76 related articles for article (PubMed ID: 1675130)
1. 'Role of bone marrow stromal cells in the growth of human multiple myeloma.
Caligaris-Cappio F; Bergui L; Gregoretti MG; Gaidano G; Gaboli M; Schena M; Zallone AZ; Marchisio PC
Blood; 1991 Jun; 77(12):2688-93. PubMed ID: 1675130
[TBL] [Abstract][Full Text] [Related]
2. Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα.
Akhmetzyanova I; Aaron T; Galbo P; Tikhonova A; Dolgalev I; Tanaka M; Aifantis I; Zheng D; Zang X; Fooksman D
Blood Adv; 2021 Sep; 5(18):3592-3608. PubMed ID: 34550328
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F; Tangredi C; Dal Bo M; Toffoli G
Front Oncol; 2024; 14():1370854. PubMed ID: 38655136
[TBL] [Abstract][Full Text] [Related]
4. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.
Bou Zerdan M; Nasr L; Kassab J; Saba L; Ghossein M; Yaghi M; Dominguez B; Chaulagain CP
Int J Hematol Oncol; 2022 Apr; 11(2):IJH39. PubMed ID: 35663420
[TBL] [Abstract][Full Text] [Related]
5. Biomimetic 3D Environment Based on Microgels as a Model for the Generation of Drug Resistance in Multiple Myeloma.
Marín-Payá JC; Díaz-Benito B; Martins LA; Trujillo SC; Cordón L; Lanceros-Méndez S; Gallego Ferrer G; Sempere A; Gómez Ribelles JL
Materials (Basel); 2021 Nov; 14(23):. PubMed ID: 34885273
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Disorders in Multiple Myeloma.
Gavriatopoulou M; Paschou SA; Ntanasis-Stathopoulos I; Dimopoulos MA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768861
[TBL] [Abstract][Full Text] [Related]
7. CD138
Wu D; Zhang P; Li F; Shen Y; Chen H; Feng Y; He A; Wang F
Aging (Albany NY); 2020 Nov; 12(22):23067-23081. PubMed ID: 33197893
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Features of Multiple Myeloma.
El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
[TBL] [Abstract][Full Text] [Related]
9. Unusual malignant neoplasms occurring around dental implants: A report of 2 cases.
Oh SH; Kang JH; Seo YK; Lee SR; Choi YS; Hwang EH
Imaging Sci Dent; 2018 Mar; 48(1):59-65. PubMed ID: 29581951
[TBL] [Abstract][Full Text] [Related]
10. Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.
Furukawa M; Ohkawara H; Ogawa K; Ikeda K; Ueda K; Shichishima-Nakamura A; Ito E; Imai JI; Yanagisawa Y; Honma R; Watanabe S; Waguri S; Ikezoe T; Takeishi Y
J Biol Chem; 2017 Mar; 292(10):4280-4292. PubMed ID: 28154173
[TBL] [Abstract][Full Text] [Related]
11. NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells.
Zahedi S; Shamsasenjan K; Movassaghpour A; Akbarzadehlaleh P
Adv Pharm Bull; 2016 Sep; 6(3):415-422. PubMed ID: 27766226
[No Abstract] [Full Text] [Related]
12. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
Colombo M; Galletti S; Bulfamante G; Falleni M; Tosi D; Todoerti K; Lazzari E; Crews LA; Jamieson CH; Ravaioli S; Baccianti F; Garavelli S; Platonova N; Neri A; Chiaramonte R
Oncotarget; 2016 Aug; 7(35):56013-56029. PubMed ID: 27463014
[TBL] [Abstract][Full Text] [Related]
13. Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.
de la Puente P; Quan N; Hoo RS; Muz B; Gilson RC; Luderer M; King J; Achilefu S; Salama NN; Vij R; Azab AK
Haematologica; 2016 Jul; 101(7):e307-11. PubMed ID: 27081175
[No Abstract] [Full Text] [Related]
14. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional tissue culture model to study primary human bone marrow and its malignancies.
Parikh MR; Belch AR; Pilarski LM; Kirshner J
J Vis Exp; 2014 Mar; (85):. PubMed ID: 24637629
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug resistance: an evolving paradigm.
Holohan C; Van Schaeybroeck S; Longley DB; Johnston PG
Nat Rev Cancer; 2013 Oct; 13(10):714-26. PubMed ID: 24060863
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.
Atsuta I; Liu S; Miura Y; Akiyama K; Chen C; An Y; Shi S; Chen FM
Stem Cell Res Ther; 2013; 4(5):111. PubMed ID: 24025590
[TBL] [Abstract][Full Text] [Related]
18. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
19. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.
McMillin DW; Negri JM; Mitsiades CS
Nat Rev Drug Discov; 2013 Mar; 12(3):217-28. PubMed ID: 23449307
[TBL] [Abstract][Full Text] [Related]
20. DangER: protein ovERload. Targeting protein degradation to treat myeloma.
Aronson LI; Davies FE
Haematologica; 2012 Aug; 97(8):1119-30. PubMed ID: 22580998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
